Gout Therapeutics Market, Updated Guideline For 2020

The global Gout Therapeutics Market is expected to reach a value of USD 8.3 billion by 2025.

Top Key Players in Gout Therapeutics Market are Takeda Pharmaceutical Company, Novartis, AstraZeneca, GlaxoSmithKline, Merck, and Regeneron Pharmaceuticals.

     The updated 2020 guidelines from the American College of Rheumatology focus on establishing a standard treat-to-target urate lowering therapy. New Clinical evidence based on the latest clinical trials has prompted releasing updated guidelines that will improve patient care for the affected population. Standardization of a treat-to-target strategy for urate lowering therapy is the key focus because of its benefit for all patients with gout.

     Takeda Pharmaceutical Company Limited (“Takeda”), Aug 2020 presented three abstracts at the 72nd National Hemophilia Foundation’s Bleeding Disorders Conference, underscoring the need for real-world evidence (RWE) to advance patient-centric treatment in bleeding disorders.

     RWE from these studies highlight the ongoing unmet clinical need for diagnosis, personalization and treatment optimization in patients with hemophilia and von Willebrand’s disease (VWD). Takeda’s presence at NHF Bleeding Disorders Conference includes the following presentations, which are intended for scientific discussion only.

      Urate-lowering therapy (ULT) may reduce the risk for type 2 diabetes (T2D) in patients with gout, according to study results published in 2020Biomedical Research International. While gout is a known risk factor for T2D, the relationship between ULT and  T2D risk remains unclear. Results suggest that ULT may mitigate the risk for T2D in patients with gout. However, unmeasured confounders may have introduced bias to study findings; data on uric acid levels and lifestyle, including smoking status, alcohol consumption, and family history, were unavailable. Further research is necessary to assess the link between ULT and T2D.

          A treat-to-target therapy approach with urate lowering treatment (ULT) in patients with gout is associated with a significant reduction of ultrasound-detected crystal depositions after 12 months, according to study results published in Annals of the Rheumatic Diseases. Monosodium urate crystals can be identified using ultrasound or dual-energy computed tomography; both tests are included in the American College of Rheumatology/European League against Rheumatism (ACR/EULAR) classification criteria for gout.

      May2029 Researchers were invited to contribute with manuscripts with in vitro, in vivo, and clinical studies focusing not only on the effects of natural products on the control of uric acid levels but also on potential treatments to reduce the gouty inflammatory arthritis. The topics of this Special Issue included: (1) sources of natural products used in the treatment of gout; (2) isolation and characterization of natural products useful in gout control; (3) natural products which increase uric acid excretion and/or reduce uric acid absorption; (4) natural products with antioxidant and anti-inflammatory effects in gout; (5) natural products which reduce uric acid biosynthesis or enhance its degradation; (6) comparison of natural and synthetic drugs in gout treatment; (7) safety of gout control with natural products; (8) chemical modifications of natural products useful in gout control to improve their efficacy

     Based on drug class, the global gout therapeutics industry is segmented into non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, colchicine, and urate lowering agents. On the basis of disease condition, the industry is segmented into acute and chronic gout. On the basis of region it has splits into North America, Europe, Asia-Pacific and RoW.  North America dominated the industry in 2020 due to due to the presence of major market players, affordability for high cost biologics and urate lowering agents, early introduction of drugs in the US, and presence of large patient base. Gout is common in most countries in North America affecting around 8.3 million people in the United States, with prevalence in the 1–4% range.

      This report studies the Gout Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Gout Therapeutics market by product type and applications/end industries.

Interested in the Report just Click on below link:
For more information contact @

About author


Quisque sed tristique felis. Lorem visit my website amet, consectetur adipiscing elit. Phasellus quis mi auctor, tincidunt nisl eget, finibus odio. Duis tempus elit quis risus congue feugiat. Thanks for stop Tech Blog!

Scroll to Top